Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria for Participants with Diabetic Foot Ulcers:~1. Participant is at least 18 years old~2. Participant is willing and capable of complying with all protocol requirements~3. Participant or legally authorized representative (LAR) is willing to provide written informed consent~4. Participant has Type 1 or Type 2 diabetes (criteria for the diagnosis of diabetes mellitus per American Diabetes Association)~5. Ulcer(s) must be located at least in part on the foot or ankle~6. Ulcer(s) must be present for more than 28 days prior to randomization and initial application of study product, and has not adequately responded to conventional ulcer therapy~7. Wound size must be \>1.0 cm\^2 and \< 25 cm\^2 on the day of randomization and initial application of the study product, after initial debridement~8. Participant has adequate circulation to the affected extremity(ies), as demonstrated by at least ONE of the following within 60 days prior to enrollment/randomization:~   1. Dorsum transcutaneous oxygen test (TcPO2) of study leg(s) with results ≥40mmHg, OR~  2. Ankle-Brachial Index (ABI) of study leg(s) with results of ≥ 0.7 and ≤ 1.3, OR~  3. Toe-Brachial Index (TBI) of study extremity(ies) with results of ≥ 0.5~Exclusion Criteria for Participants with Diabetic Foot Ulcers:~1. Participant has been previously enrolled into this study, or is currently participating in another prospective drug or device study that has not reached its primary endpoint~2. Participant is pregnant, breast feeding or planning to become pregnant~3. Participant has a known allergy to resorbable suture materials, e.g. Polyglactin 910 (PGLA), Polydioxanone (PDS)~4. Participant has a life expectancy less than six months as assessed by the investigator~5. Participant has received skin substitutes during the screening period or within 14 days prior to beginning of screening period~6. Participant has an additional wound within 3 cm of the study wound(s) or study wounds are less than 3 cm apart~7. Hgb A1c \> 12 percent within 3 months prior to randomization~8. Participant not in reasonable metabolic control in the judgment of the investigator~9. Participant with a known history of poor compliance with medical treatments~10. Participant currently undergoing cancer treatment~11. Participant has been diagnosed with at least one of the following autoimmune connective tissue diseases: lupus, vasculitis, sickle cell, or uncontrolled rheumatoid arthritis~12. Participant is taking parenteral corticosteroids or any cytotoxic agents for 7 consecutive days during the screening period or up to 30 days before the screening period. Chronic oral steroid use is not excluded if dose is \< 10 mg per day for prednisone.~13. Active infection, undrained abscess, or critical colonization of the wound(s) with bacteria in the judgment of the investigator~14. Osteomyelitis or exposed bone, probes to bone or joint capsule on investigator's exam or radiographic evidence~15. Participant unwilling or unable to safely utilize appropriate offloading device to unweight wound(s)~16. Study ulcer(s) experiences greater than 30 percent reduction over the 2-week screening period~17. Participant also has a venous leg ulcer that is enrolled into this study~Inclusion Criteria for Participants with Venous Leg Ulcers:~1. Participant is at least 18 years old~2. Participant is willing and capable of complying with all protocol requirements~3. Participant or legally authorized representative (LAR) is willing to provide written informed consent~4. Participant has peripheral venous disease per investigator judgment or diagnostic confirmation~5. Ulcer(s) must be venous in origin, located on a lower extremity~6. Ulcer(s) must be present for more than 28 days prior to randomization and initial application of study product, and has not adequately responded to conventional ulcer therapy~7. Wound(s) size must be \>1.0 cm\^2 and \< 50 cm\^2 on the day of randomization and initial application of the study product, after initial debridement~8. Participant has adequate circulation to the affected extremity(ies), as demonstrated by at least ONE of the following within 60 days prior to enrollment/randomization:~   1. Dorsum transcutaneous oxygen test (TcPO2) of study leg(s) with results ≥ 40mmHg, OR~  2. Ankle-brachial index (ABI) of study leg(s) with results of ≥ 0.7 and ≤ 1.52, OR~  3. Toe-Brachial Index (TBI) of study leg(s) with results of ≥ 0.5, OR~  4. Doppler arterial waveforms, which are triphasic or biphasic at the ankle of the affected leg(s)~Exclusion Criteria for Participants with Venous Leg Ulcers:~1. Participant has been previously enrolled into this study, or is currently participating in another prospective drug or device study that has not reached its primary endpoint~2. Participant is pregnant, breast feeding or planning to become pregnant~3. Participant has a known allergy to resorbable suture materials, e.g. Polyglactin 910 (PGLA), Polydioxanone (PDS)~4. Participant has a known allergy to bovine materials or agarose shipping materials~5. Participant has a life expectancy less than six months as assessed by the investigator~6. Participant has received skin substitutes during the screening period or within 14 days prior to the beginning of the screening period~7. Participant has an additional wound within 3 cm of the study wound or study wounds are less than 3 cm apart~8. Hgb A1c \> 12 percent within 3 months prior to randomization in patients with a known history of diabetes~9. Participant is not in reasonable metabolic control in the judgment of the investigator~10. Participant has a known history of poor compliance with medical treatments~11. Participant currently undergoing cancer treatment~12. Participant has been diagnosed with at least one of the following autoimmune connective tissue diseases: lupus, vasculitis, sickle cell, or uncontrolled rheumatoid arthritis~13. Participant is taking parenteral corticosteroids or any cytotoxic agents for 7 consecutive days during the screening period or up to 30 days before the screening period. Chronic oral steroid use is not excluded if dose is \< 10 mg per day for prednisone.~14. Active infection, undrained abscess, or critical colonization of the wound(s) with bacteria in the judgment of the investigator~15. Participant unwilling or unable to tolerate use of compression therapy for the duration of the study~16. Study ulcer(s) experiences greater than 30 percent reduction over the 2-week run-in period~17. Participant also has a diabetic foot ulcer that is enrolled into this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®) (Type: EXPERIMENTAL): Biweekly (every 2 weeks) application for either 12 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)
- Diabetic Foot Ulcer Participants Assigned to Standard of Care (Type: ACTIVE_COMPARATOR): Weekly application for either 12 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)
- Venous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®) (Type: EXPERIMENTAL): Biweekly (every 2 weeks) application for either 16 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)
- Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®) (Type: ACTIVE_COMPARATOR): Biweekly (every 2 weeks) application for either 16 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)

Based on this trial design, predict the completion outcome and termination type (if applicable).